Pharmacodynamic Modeling of the Effects of Lanreotide Autogel on Growth Hormone and Insulin-Like Growth Factor 1

Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly

(2014) G. Lombardi et al.   JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION

The current status of IGF-I assays – A 2009 update

(2009) Jan Frystyk et al.   GROWTH HORMONE & IGF RESEARCH

Guidelines for Acromegaly Management: An Update

(2009) S. Melmed et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Semiparametric Distributions With Estimated Shape Parameters

(2009) Klas J. F. Petersson et al.   PHARMACEUTICAL RESEARCH

Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension

(2009) Shlomo Melmed et al.   Pituitary

Control of IGF-I levels with titrated dosing of lanreotide Autogel over 48weeks in patients with acromegaly

(2008) Philippe Chanson et al.   CLINICAL ENDOCRINOLOGY

Significant tumour shrinkage after 12 months of lanreotide Autogel-120 mg treatment given first-line in acromegaly

(2008) Annamaria Colao et al.   CLINICAL ENDOCRINOLOGY

Population Pharmacokinetic Analysis of Lanreotide Autogel® in Healthy Subjects

(2008) Iñaki F Trocóniz et al.   CLINICAL PHARMACOKINETICS

Population PK and PK/PD modelling of microencapsulated octreotide acetate in healthy subjects

(2003) Honghui Zhou et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY